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Dear Editor,
Kerstjens and colleagues1 are tobecommended for publishing
their data on effects of a CCR1 chemoreceptor antagonist in
patients with moderate to severe COPD. The findings,
although disappointing, are of interest. The study drug
represents a new class of agents with some known effects on
traffic of leukocytes in inflamed lungs. As a rationale for their
study Kerstjens et al refer to unpublished findings in LPS-
challenged animals demonstrating that the CCR1 antagonist
effectively reduced the number of neutrophils occurring in
the airway lumen. Traditionally, reduced lumen granulocytes
may have been considered evidence for anti-inflammatory
efficacy. However, we argue that this notion is not always
tenable. Indeed, such an effect could be severely pro-
inflammatory: Several experimental in vivo studies have
been published during the last decade indicating that
a reduced number of inflammatory leukocytes (neutrophils,
eosinophils, lymphocytes.) in the airway lumen can be asso-
ciated with highly significant, even lethal worsening of
airway-lung inflammation. This ’paradoxical’ result has been
produced by a variety of interventions including different
classes of experimental drugs (reviewed in 2,3). Perhaps the
findings are not that paradoxical if one considers a wealth of
published patient data indicating that the resolution phase of
airway inflammatory conditions is associated with increasing
numbers of leukocytes in the airway lumen.2,3 The inference
here is that the opposite result (a decreased number of lumen
leukocytes) could be associated with worsening of the airway
inflammation. Any intervention causing reduced numbers of
airway lumen leukocytes should thus be considered a serious
risk until proven otherwise. The explanation is quite simple.
The less the leukocytes canmoveacross theepithelial lining to
beeliminated into the lumenthemore theywill remainandbe
active in the diseased airway wall.
There is no information on leukocyte numbers in the
bronchial wall and lumen of the COPD subjects in the study by
Kerstjens et al. Until such patient data become available it is
nevertheless important to try and further interpret the nega-
tive outcome. Contrasting the authors’ expectation the CCR1DOI of original article: 10.1016/j.rmed.2010.04.010.
0954-6111/$ - see front matter ª 2011 Elsevier Ltd. All rights reserved
doi:10.1016/j.rmed.2011.05.018antagonist caused marked worsening of the evening lung
function (peak expiratory flow; p < 0.01 compared to
placebo). Furthermore, one of the individuals treatedwith the
CCR1 antagonist exhibited a severe exacerbation requiring
hospitalisation. The authors reported that the exacerbation
was not considered related to the treatment, but the reasons
for this conclusion are not given. In the light of the risk with
drugs interfering with transepithelial elimination of disease-
driving leukocytes (discussed above), it is possible that the
adverse outcome of the CCR1 antagonist trial reflected
reduced elimination of leukocytes from bronchial mucosal
tissues. The human airway importance of transepithelial
elimination is currentlybestdemonstratedbystudies involving
asthmatic individuals showing reduced numbers of bronchial
tissue leukocytes along with correspondingly increased
numbers of bronchial lumen cells. 2,3The CCR1 antagonist
study byKerstjens et almay have addeda furtherdimension to
the clinical importance of the transepithelial mode of ridding
the bronchial mucosa of disease-driving cells.
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